- Home
- NBIX vs FMS Comparison
NBIX vs FMS Comparison
Compare NBIX & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- FMS
- Stock Information
- Founded
- NBIX 1992
- FMS 1996
- Country
- NBIX United States
- FMS Germany
- Employees
- NBIX N/A
- FMS N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- FMS Misc Health and Biotechnology Services
- Sector
- NBIX Health Care
- FMS Health Care
- Exchange
- NBIX Nasdaq
- FMS Nasdaq
- Market Cap
- NBIX 12.4B
- FMS 15.9B
- IPO Year
- NBIX 1996
- FMS 1996
- Fundamental
- Price
- NBIX $134.33
- FMS $27.05
- Analyst Decision
- NBIX Strong Buy
- FMS Hold
- Analyst Count
- NBIX 21
- FMS 1
- Target Price
- NBIX $165.14
- FMS $30.00
- AVG Volume (30 Days)
- NBIX 821.3K
- FMS 338.6K
- Earning Date
- NBIX 07-30-2025
- FMS 07-29-2025
- Dividend Yield
- NBIX N/A
- FMS 2.11%
- EPS Growth
- NBIX N/A
- FMS 27.83
- EPS
- NBIX 2.96
- FMS 2.28
- Revenue
- NBIX $2,412,600,000.00
- FMS $21,068,786,202.00
- Revenue This Year
- NBIX $16.29
- FMS $2.74
- Revenue Next Year
- NBIX $15.08
- FMS $3.60
- P/E Ratio
- NBIX $45.11
- FMS $24.09
- Revenue Growth
- NBIX 21.73
- FMS 0.10
- 52 Week Low
- NBIX $84.23
- FMS $17.93
- 52 Week High
- NBIX $157.98
- FMS $30.46
- Technical
- Relative Strength Index (RSI)
- NBIX 70.92
- FMS 39.69
- Support Level
- NBIX $127.03
- FMS $26.16
- Resistance Level
- NBIX $135.94
- FMS $28.87
- Average True Range (ATR)
- NBIX 2.85
- FMS 0.31
- MACD
- NBIX 0.47
- FMS -0.12
- Stochastic Oscillator
- NBIX 87.52
- FMS 12.92
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About FMS Fresenius Medical Care AG
Fresenius Medical Care is the largest dialysis company in the world, treating about 300,000 patients from nearly 3,700 clinics worldwide as of December 2024. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.